Viagra-like drug slows Alzheimer’s in some patients claims research

LONDON: A Viagra-like drug could slow Alzheimer’s disease, its manufacturer’s trial results suggest.

The once-daily pill slowed decline by 31 per cent over a year among patients who were not already taking standard Alzheimer’s medicines.

The benefit was in 604 of 1,535 patients. Across the whole trial, researchers could not establish a significant benefit.

The findings of the international trial, whose lead investigator was based at Stanford University, were presented at the Clinical Trials on Alzheimer’s Disease conference in Boston.

The experimental treatment, called AR1001, contains mirodenafil, a drug developed to treat erectile dysfunction.

It belongs to the same family of medicines as Viagra, but is a different drug, and the findings do not establish that Viagra itself can treat Alzheimer’s.

Researchers believe AR1001 could protect brain cells by acting on several processes involved in Alzheimer’s, including inflammation and changes to the tau protein.

Dr Sheona Scales, director of research at Alzheimer’s Research UK, said: “These are very encouraging results, marking an important milestone in the search for new Alzheimer’s treatments.”

She said the drug was particularly interesting because it was a tablet that worked differently from existing treatments, targeting several processes involved in brain function.

The trial involved 1,535 people with early Alzheimer’s across 13 countries, including Britain.

Participants received either AR1001 or a dummy pill, with researchers tracking their memory, thinking and ability to manage everyday tasks over a year.

The benefit was seen among 604 patients who were not already taking standard Alzheimer’s medicines. In this group, those taking AR1001 deteriorated 31 per cent more slowly than those given the dummy pill.

However, when researchers looked at all 1,535 patients together, including those already taking other Alzheimer’s medicines, they could not establish a significant benefit.

Dr Scales said: “The trial demonstrated a statistically significant slowing of clinical decline in participants who were not taking other commonly used Alzheimer’s medications alongside the trial drug. However, this benefit was not significant across the overall trial group.”

It is not yet clear why the drug worked for patients who were not taking other Alzheimer’s medicines.

These included memantine and medicines known as acetylcholinesterase inhibitors, which are used to treat Alzheimer’s symptoms.

Dr Richard Oakley, associate director for research and innovation at Alzheimer’s Society, said: “These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer’s disease that tackles its causes, not just its symptoms.

“It’s fantastic to see research and clinical trials unlocking promising new ways to target Alzheimer’s Disease. AR1001 takes a novel approach, relaxing blood vessels to increase blood flow to the brain. And unlike other disease-modifying treatments that have shown benefit in late-stage trials, it is taken as a once-a-day tablet, which could make treatment simpler.”

Impact measured on memory, judgment and everyday abilities.

Researchers measured deterioration using an 18-point scale assessing memory, judgment and everyday abilities.

Over the year, patients taking AR1001 in the smaller group deteriorated by 0.44 points less than those given the dummy pill.

This represented a 31 per cent reduction in the rate of decline, rather than an improvement in patients’ existing symptoms.

Other tests of thinking and daily functioning also favoured the drug, although several differences were not statistically significant.

Tests of spinal fluid provided evidence that the drug was acting on its intended biological target within the brain and nervous system.

AR1001 blocks an enzyme called PDE5, increasing a chemical signal involved in several processes that researchers believe could help protect brain cells.

Dr Sharon Sha, chief of the Memory Disorders Division at Stanford University and global principal investigator of the trial, said the results among patients not taking other Alzheimer’s medicines were encouraging, as was the drug’s safety record.

She said further research was needed to understand its effects.

“The work of POLARIS-AD is another step towards filling an unmet need in Alzheimer’s disease in which patients need more options for treatment,” she said.

AriBio, the company developing AR1001, plans to discuss the findings with US regulators, a potential step towards seeking approval for the pill as an Alzheimer’s treatment.

Company says findings ‘very encouraging’

Dr David Greeley of AriBio, who led the drug’s earlier Phase 2 trial, said the findings were “very encouraging”.

He said: “If approved, this oral drug would broaden patients’ options.”

He added: “Further evaluation is needed, but our goal is meaningful treatment that not only helps patients but that can be realistically afforded, received and sustained.”

The company said the drug was generally well tolerated, with serious adverse events reported in similar proportions of the treatment and placebo groups.

Diarrhoea, falls and dizziness were among the most common adverse events. About 5 per cent stopped the drug because of adverse events, compared with 2 per cent receiving a placebo.

Most participants who completed the first year entered an extension study, in which everyone received the drug. It is expected to finish next year.

Dr Scales said: “We look forward to seeing whether these benefits are sustained over the longer term.”

Researchers said they closely monitored “unwanted sexual behaviour” during the trial and no significant signal had been reported.